Old news, but see highlighted part of the quote:
KENSINGTON, Md.--(BUSINESS WIRE)--Oct. 25, 1999--Nymox
Pharmaceutical Corp. (Nasdaq:NYMX.O) today announced that a method for
treating Alzheimer's Disease to which it has certain rights has shown
promise in early studies conducted by Dr. Ben Wolozin, M.D., Ph.D., of
the Loyola University Medical Center in Chicago, IL. Dr. Wolozin has
licensed the commercial rights to his discoveries in this area to
Nymox.
Dr. Wolozin presented the results of a study tracking the rates
of Alzheimer's Disease among some 50,000 patients at three major U.S.
medical centers at the annual meeting of the Society for Neuroscience
in Miami Beach, FL, on October 24, 1999.
"We found that the rate of Alzheimer's Disease for patients
taking two kinds of a type of an anti-cholesterol known as statin --
lovastatin (Mevacor) and pravastatin (Pravachol) -- was reduced by 60
percent to 73 percent compared to a total patient population or
compared to patients taking other medications typically used to treat
cardiovascular disease or hypertension," said Dr. Wolozin. "Our
studies suggests that these two drugs may protect against Alzheimer's
Disease."
Dr. Michael Munzar, M.D., medical director of Nymox, said that
"while these findings need to be further verified, they might offer a
potentially new and exciting approach to the treatment of this dread
disease, which is now the fourth-leading cause of death among the
elderly in the U.S.
"This appears to be the first time that a statin drug has been
demonstrated in a large study to be associated with reduced
Alzheimer's Disease incidence.
>>>>>>>The reduction in the rate of
Alzheimer's Disease among the patients taking these two drugs is greater than other proposed therapeutics for the disease investigated to date. <<<<<<<
An additional positive feature is that these drugs are FDA
approved, in common medical use, and well-tolerated by patients," Dr.
Munzar added.
Nymox Pharmaceutical Corp. pioneers in the research and
development of products for the diagnosis and treatment of Alzheimer's
disease, an affliction for more than 20 million people around the
world. Nymox offers the world's only accurate, non-invasive test to
aid in the diagnosis of the disease, and is developing proprietary
Spheron-based drug therapies that could lead to effective treatment of
Alzheimer's disease. Nymox also is developing unique drug therapies to
treat E. coli infections and urinary tract infections, which have
become highly resistant to conventional antibiotic treatments.
RWR |
